Tenofovir alafenamide prevents HBV reactivation in anticancer/immunosuppression: 24-month multicentre prospective study - PubMed

6 hours ago

Tenofovir alafenamide (TAF) effectively prevents HBV reactivation and reactivation-related hepatitis over a 24-month period.
The study involved 191 patients, with 150 evaluable at 12 months and 127 at 24 months.
No cases of HBV reactivation, reactivation-related hepatitis, or therapy interruption occurred during the first 12 months.
Between months 12-24, four patients discontinued TAF, but none of the remaining patients experienced reactivation or related issues.
Virologic relapse occurred in one patient after TAF discontinuation, but re-initiation of TAF prevented further complications.
No reactivation was observed in patients who switched to entecavir or those on high-risk regimens.
No adverse events led to TAF discontinuation.

Hasty Briefsbeta